Study of AZD0466 monotherapy or in combination in patients with advanced haematological malignancies

Study identifier:D8241C00001

ClinicalTrials.gov identifier:NCT04865419

EudraCT identifier:2020-005106-25

CTIS identifier:N/A

Terminated/Withdrawn

Official Title

A Modular Phase I/II, Open-Label, Multi-Centre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of AZD0466 Monotherapy or in Combination in Patients with Advanced Haematological Malignancies

Medical condition

Haematological Malignancies

Phase

Phase 1

Healthy volunteers

No

Study drug

AZD0466, Voriconazole

Sex

All

Actual Enrollment

46

Study type

Interventional

Age

18 Years - 130 Years

Date

Study Start Date: 11 Jun 2021
Primary Completion Date: 08 Aug 2023
Study Completion Date: 08 Aug 2023

Study design

Allocation: Non-randomized
Endpoint Classification: -
Intervention Model: Parallel Assignment
Masking: -
Primary Purpose: Treatment

Verification:

Verified 01 Jul 2024 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria